Figure 5.
RvE1 regulates pathogenic T cell IL-17A and IFN-γ production. a,b Representative FACS plots showing IFN-γ and IL-17A in CD4+ T cells from spleen, MLN and lung of day 21 mice treated with RvE1 or vehicle. Percentages of IFN-γ+ and IL-17A+ a and the ratio of IFN-γ+ to IL-17A+ b CD4+ T cells in spleen, MLN and lung are indicated after treatment with vehicle (white) or RvE1 (black). c, BALF cells at day 21 were counted after anti-IL-17A, rmIL-17A or RvE1 plus rmIL-17A (left) and in separate experiments after RvE1, rmIL-23 or RvE1 plus rmIL-23 (right) (See Methods) d, Mice were given IL-6, anti-IFN-γ alone or in combination with RvE1 on days 18-20 and BALF cells were enumerated. e, Representative lung tissue sections stained with H&E from day 21 mice treated with an isotype control antibody, anti-IL-17A, RvE1 or RvE1 plus anti-IFN-γ (see Methods). Original magnification ×100. Br; bronchus, V; vein. *, P < 0.05 compared to vehicle or isotype control; †, P < 0.05 compared to anti- IL-17, #, P < 0.05 compared to RvE1 by one-way ANOVA for n ≥ 4 in ≥ 2 independent experiments.